Document Detail

Untapped therapeutic potential of surfactant proteins: is there a case for recombinant SP-D supplementation in neonatal lung disease?
MedLine Citation:
PMID:  20551708     Owner:  NLM     Status:  MEDLINE    
Whilst pulmonary surfactant therapy has been highly successful in reducing mortality from respiratory distress syndrome of the newborn, a significant proportion of infants born at less than 28 weeks' gestation develop neonatal chronic lung disease. This has a complex pathogenesis but infection, inflammation, oxygen toxicity and ventilator-induced lung injury in the premature infant are all recognised risk factors for its development. Current surfactant therapies in clinical use do not contain all surfactant components and lack the hydrophilic surfactant proteins A and D. These proteins are known to have important roles in surfactant homeostasis and in protecting the lung against inflammation. This review examines the evidence from animal models supporting a role for surfactant protein-D in particular in reducing inflammation in the lung and speculates that supplementation of current surfactant therapies with recombinant forms of surfactant protein-D may help offset the risk of development of chronic lung disease.
Howard W Clark
Related Documents :
2007938 - Effects of two rescue doses of a synthetic surfactant on mortality rate and survival wi...
3575008 - Evaluation of routine lumbar punctures in newborn infants with respiratory distress syn...
15238918 - Airway eicosanoids in acute severe respiratory syncytial virus bronchiolitis.
24853888 - Iron stores of breastfed infants during the first year of life.
18425878 - Delayed introduction of progressive enteral feeds to prevent necrotising enterocolitis ...
8632928 - Can asphyxiated infants at risk for neonatal seizures be rapidly identified by current ...
Publication Detail:
Type:  Journal Article; Review     Date:  2010-06-10
Journal Detail:
Title:  Neonatology     Volume:  97     ISSN:  1661-7819     ISO Abbreviation:  Neonatology     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-06-16     Completed Date:  2010-09-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101286577     Medline TA:  Neonatology     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  380-7     Citation Subset:  IM    
Copyright Information:
Copyright 2010 S. Karger AG, Basel.
Department of Child Health, Southampton General Hospital, University of Southampton, Southampton, UK. h.w.clark @
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Disease Models, Animal
Infant, Newborn
Infant, Newborn, Diseases / drug therapy,  pathology
Models, Biological
Pulmonary Surfactant-Associated Protein D / therapeutic use*
Pulmonary Surfactants / therapeutic use*
Recombinant Proteins / therapeutic use
Respiratory Distress Syndrome, Newborn / drug therapy*,  pathology
Surface-Active Agents / therapeutic use
Reg. No./Substance:
0/Pulmonary Surfactant-Associated Protein D; 0/Pulmonary Surfactants; 0/Recombinant Proteins; 0/Surface-Active Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Enhancing functional maturity before preterm birth.
Next Document:  Pulmonary and neurological follow-up of extremely preterm infants.